Dysport
Dysport is a major botulinum toxin type A brand associated with Ipsen, with Galderma holding aesthetic commercialization rights in licensed territories including the United States. Its nonproprietary name is abobotulinumtoxinA.
Dysport often appears with larger numeric unit amounts than some other type A products. Those numbers are not a conversion scale. They reflect product-specific potency testing, labeling, and clinical-study context rather than a universal botulinum toxin unit.
Who Makes Dysport?
Section titled “Who Makes Dysport?”Ipsen Biopharm Ltd. manufactures Dysport, as identified in the current Dysport prescribing information on DailyMed 🔗. Galderma commercializes Dysport for aesthetic use in licensed territories, including the United States, but that commercial role does not make Galderma the product’s manufacturer.
Product Identity
Section titled “Product Identity”| Field | Reference point |
|---|---|
| Brand | Dysport |
| Nonproprietary name | AbobotulinumtoxinA |
| Toxin type | Botulinum toxin type A |
| Product origin | Ipsen |
| Manufacturer | Ipsen Biopharm Ltd. |
| Aesthetic commercialization | Galderma in licensed territories |
Label Context
Section titled “Label Context”FDA approved Dysport on April 29, 2009 for cervical dystonia and glabellar lines (FDA original approval letter 🔗). Its current U.S. scope also includes spasticity.
The Dysport prescribing information 🔗 defines three indication groups:
| U.S. indication | Patient limits |
|---|---|
| Cervical dystonia | Adults |
| Temporary improvement of moderate to severe glabellar lines associated with procerus and corrugator muscle activity | Adults younger than 65 years |
| Spasticity | Patients 2 years of age and older |
Dysport’s U.S. aesthetic indication does not include lateral canthal lines, forehead lines, or platysma bands. The U.S. FDA indication matrix separates those treatment areas across products without implying equivalent units or dosing.
Regional availability also matters. A Dysport claim supported in one country or product-information document should not be copied into another market without checking the local label.
Porton Down Development History
Section titled “Porton Down Development History”Dysport’s history runs through the Centre for Applied Microbiology and Research at Porton Down, where a UK therapeutic botulinum toxin preparation was developed and produced for clinical research. A peer-reviewed history of abobotulinumtoxinA 🔗 traces the later path through Porton International and successor companies. Peter Hambleton, Ph.D. represents the upstream scientific and production stage.
The later commercial pathway involved Porton International and successor companies before the product entered the current Ipsen structure. This history explains Dysport’s origin; it does not replace current manufacturer, approval, label, or Galderma commercialization information.
Market Interpretation
Section titled “Market Interpretation”Dysport is a durable comparison point because it sits beside Botox and Xeomin in many professional and consumer discussions. It is not directly interchangeable with those brands: type A products can share broad biology while differing in formulation, labeling, unit language, and market position.
Galderma’s aesthetic commercialization role also has a current leadership dimension. Flemming Ørnskov connects Galderma’s company strategy to Dysport commercialization and the separate development of Relfydess. That portfolio context does not change Ipsen Biopharm’s manufacturing role or Dysport’s product-specific label.